Soft contact lenses eyed as new solutions to monitor ocular health conditions
CAPTION
Rose-tinted contact lenses (about 10 mm in diameter) containing gold nanoparticles filter out problematic colors for people with red-green color blindness.
CREDIT
Adapted from ACS Nano 2021, DOI: 10.1021/acsnano.0c09657
WEST LAFAYETTE, Ind. - New contact lens technology to help diagnose and monitor medical conditions may soon be ready for clinical trials.
A team of researchers from Purdue University worked with biomedical, mechanical and chemical engineers, along with clinicians, to develop the novel technology. The team enabled commercial soft contact lenses to be a bio instrumentation tool for unobtrusive monitoring of clinically important information associated with underlying ocular health conditions.
The team's work is published in Nature Communications. The Purdue Research Foundation Office of Technology Commercialization helped secure a patent for the technology and it is available for licensing.
"This technology will be greatly beneficial to the painless diagnosis or early detection of many ocular diseases including glaucoma" said Chi Hwan Lee, the Leslie A. Geddes assistant professor of biomedical engineering and assistant professor of mechanical engineering at Purdue who is leading the development team. "Since the first conceptual invention by Leonardo da Vinci, there has been a great desire to utilize contact lenses for eye-wearable biomedical platforms."
Sensors or other electronics previously couldn't be used for commercial soft contact lenses because the fabrication technology required a rigid, planar surface incompatible with the soft, curved shape of a contact lens.
The team has paved a unique way that enables the seamless integration of ultrathin, stretchable biosensors with commercial soft contact lenses via wet adhesive bonding. The biosensors embedded on the soft contact lenses record electrophysiological retinal activity from the corneal surface of human eyes, without the need of topical anesthesia that has been required in current clinical settings for pain management and safety.
"This technology will allow doctors and scientists to better understand spontaneous retinal activity with significantly improved accuracy, reliability, and user comfort," said Pete Kollbaum, the Director of the Borish Center for Ophthalmic Research and an associate professor of optometry at Indiana University who is leading clinical trials.
